References
- Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005;5:655–62.
- Bhattacharyya N. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. Laryngoscope 2003;113:368–72.
- Sarini J, Fournier C, Lefebvre JL, Bonafos G, Van JT, Coche-Dequéant B. Head and neck squamous cell carcinoma in elderly patients: a long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg 2001;127:1089–92.
- Jones AS, Beasley N, Houghton D, Husband DJ. The effects of age on survival and other parameters in squamous cell carcinoma of the oral cavity, pharynx and larynx. Clin Otolaryngol 1998;23:51–6.
- Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 2007;26:2791–8.
- Khalkhali-Ellis Z. Maspin: the new frontier. Clin Cancer Res 2006;12:7279–83.
- Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of MASPIN. J Cell Physiol 2006;209:617–24.
- Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006;51:31–9.
- Yoshizawa K, Nozaki S, Okamune A, Kitahara H, Ohara T, Kato K, Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. J Oral Pathol Med 2009;38:535–9.
- Marioni G, Staffieri C, Staffieri A, de Filippis C, Blandamura S. MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma. Emerging evidence and therapeutic perspectives. Acta Otolaryngol 2009;129:476–80.
- Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 2005;46:576–82.
- Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006;32:504–15.
- Sobin LH, Gospodarowicz MK, Wittekind C. editors. 2009. TNM classification of malignant tumors. 7th edition. Oxford: Wiley-Blackwell.
- Jang HL, Nam E, Lee KH, Yeom S, Son HJ, Park C. Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. Int J Mod Med 2008;22:333–8.
- Marioni G, D'Alessandro E, Giacomelli L, De Filippis C, Calgaro N, Sari M, Maspin nuclear localization is related to reduced density of tumour-associated microvessels in laryngeal carcinoma. Anticancer Res 2006;26:4927–32.
- Marioni G, D'Alessandro E, Giacomelli L, Staffieri A. CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J Oral Pathol Med 2010;5:361–7.
- Marioni G, Giacomelli L, D'Alessandro E, Marchese-Ragona R, Staffieri C, Ferraro SM, Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a pro-apoptotic effect? Am J Otolaryngol 2008;29:156–62.
- Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodelling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008;7:1080–90.
- Beltran AS, Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 2011;6:224–35.